Patient id: (b)(6).It was reported that on (b)(6) 2022 the 6.0x8 mm absolute pro stent was implanted in the right distal superficial femoral artery.On (b)(6) 2024 the patient had restenosis in the stented segment, which the physician has deemed as related to non-compliance with the prescribed dual antiplatelet therapy (dapt) of aspirin and clopidogrel.This led to critical ischemia in the extremity.The patient was re-admitted to the hospital and the restenosis was successfully treated with atherectomy and implantation of a stent graft.Although the physician has deemed the restenosis to be related to the non-compliance with dapt, this will be conservatively reported for restenosis of the absolute pro stent.No additional information was provided.
|
The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of restenosis of stented segment is listed in the absolute pro.035 peripheral self-expanding stent system instructions for use as an adverse events that may be associated with the use of a stent in peripheral arteries and / or biliary tree.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The treatments appears to be related to the operational context of the procedure.Additionally, per the physician, the reported stenosis appears to be unrelated to the device or the procedure as the patient failed to regularly take the prescribed dual antiplatelet medication.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|